...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31 (R)
【24h】

Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31 (R)

机译：用衣原体主要外膜蛋白辅以IC31（R）配制的疫苗诱导小鼠抗呼吸道攻击

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IC31 (R), a novel adjuvant, has been shown to be effective by increasing the levels of IFN-gamma in animal models when delivered with several antigens. Here, we tested the ability of IC31 (R), to enhance the protective ability of the Chlamydia trachomatis native major outer membrane protein (nMOMP). BALB/c mice were immunized by the intramuscular (i.m.) and subcutaneous (s.c.) routes with nMOMP + IC31 (R). Another group of animals was immunized with nMOMP + Alum and as a negative control mice were immunized with ovalbumin (Ova)+IC31 (R). Animals immunized with nMOMP +IC31 (R) developed high Chlamydia-specific IgG titers. The serum levels of IgG1 were higher than those of the IgG2a. T cells, from the spleens of mice immunized with IC31 (R)-adjuvanted nMOMP demonstrated a strong lympho-proliferative reaction to Chlamydia elementary bodies (EB) compared with the groups immunized with nMOMP + Alum or Ova + IC31 (R). A similar comparison between these groups of mice revealed that the levels of IFN-gamma in the supernatants from stimulated T-cells were significantly higher in animals immunized with nMOMP+IC31 (R). Following an intranasal challenge with C. trachomatis, the mice immunized with IC31 (R)-adjuvanted nMOMP showed significant protection. The change in body weight, an indication of the severity of the infection, was significantly less reduced in mice immunized with nMOMP+IC31 (R). Furthermore, the weight of the lungs, as well as the pulmonary Chlamydia burden, was significantly lower in the animals immunized with nMOMP+IC31 (R) when compared with the groups immunized with nMOMP+Alum or with Ova + IC31 (R). In conclusion, these results provide the rationale for further preclinical testing of IC31 (R) using other chlamydial antigens, and support the potential evaluation of this adjuvant in human vaccines against Chlamydia
机译：一种新型佐剂IC31（R）已显示在与几种抗原一起递送时通过增加动物模型中IFN-γ的水平是有效的。在这里，我们测试了IC31（R）增强沙眼衣原体天然主要外膜蛋白（nMOMP）的保护能力的能力。用nMOMP + IC31（R）通过肌内（i.m.）和皮下（s.c.）途径免疫BALB / c小鼠。另一组动物用nMOMP +明矾免疫，并且作为阴性对照，小鼠用卵清蛋白（Ova）+ IC31（R）免疫。用nMOMP + IC31（R）免疫的动物出现了衣原体特异性IgG高滴度。 IgG1的血清水平高于IgG2a。与用nMOMP +明矾或Ova + IC31（R）免疫的组相比，用IC31（R）辅助的nMOMP免疫的小鼠的脾脏中的T细胞对衣原体基本体（EB）表现出强烈的淋巴增殖反应。这些小鼠组之间的类似比较表明，在用nMOMP + IC31（R）免疫的动物中，受刺激的T细胞上清液中的IFN-γ水平明显更高。在用沙眼衣原体鼻内攻击后，用IC31（R）佐剂的nMOMP免疫的小鼠表现出明显的保护作用。在用nMOMP + IC31（R）免疫的小鼠中，体重的变化（表明感染严重程度的指标）的减少明显减少。此外，与用nMOMP + Alum或Ova + IC31（R）免疫的组相比，用nMOMP + IC31（R）免疫的动物的肺部重量以及肺衣原体负担显着降低。总之，这些结果为进一步使用其他衣原体抗原对IC31（R）进行临床前测试提供了依据，并支持对该佐剂在针对衣原体的人类疫苗中的潜在评估

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号